Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18660829 | THIADIAZOLYL DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS AND USES THEREOF | May 2024 | April 2025 | Allow | 11 | 1 | 1 | No | No |
| 18654235 | BICYCLIC COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | May 2024 | January 2026 | Allow | 20 | 1 | 1 | No | No |
| 18573601 | CRYSTALLINE HYDROCHLORIDE SALTS OF SUBSTITUTED TRYPTAMINES | December 2023 | August 2025 | Abandon | 20 | 2 | 0 | No | No |
| 18498894 | OXAZOLE COMPOUND CRYSTAL | October 2023 | May 2025 | Abandon | 18 | 1 | 0 | No | No |
| 18223290 | METHODS OF REDUCING DISEASE FLARES | July 2023 | September 2024 | Abandon | 14 | 1 | 0 | No | No |
| 18120725 | ACIDIC CANNABINOIDS AND USES THEREOF FOR ENHANCING FEMALE SEXUAL FUNCTION OR TREATING FEMALE SEXUAL DISORDERS | March 2023 | January 2026 | Abandon | 34 | 2 | 0 | No | Yes |
| 18060027 | BCKDK INHIBITORS AND/OR DEGRADERS | November 2022 | June 2025 | Allow | 31 | 2 | 1 | No | No |
| 17971421 | ORTHOESTER COMPOSITIONS FOR AFFINITY PURIFICATION OF OLIGONUCLEOTIDES | October 2022 | February 2026 | Allow | 40 | 1 | 0 | No | No |
| 17938824 | PIGMENTED SPOT FORMATION INHIBITOR, INCREASED MELANOSOME PHAGOCYTOSIS INHIBITOR, AND EPIDERMAL DIFFERENTIATION POTENCY IMPROVER | October 2022 | March 2025 | Abandon | 29 | 2 | 1 | No | No |
| 17995617 | CRYSTALLINE COMPLEXES | October 2022 | December 2025 | Allow | 38 | 0 | 1 | No | No |
| 17936821 | TOPICAL PHARMACEUTICAL COMPOSITION IN GEL FORM COMPRISING AT LEAST AMITRIPTYLINE FOR USE IN THE TREATMENT OF NEUROPATHIC PHANTOM LIMB PAIN | September 2022 | January 2025 | Abandon | 28 | 2 | 0 | No | No |
| 17933881 | METHODS OF TREATING METABOLIC DISORDERS | September 2022 | January 2025 | Abandon | 28 | 2 | 0 | No | No |
| 17896332 | TRIS(ALKOXYCARBONYLAMINO)TRIAZINE COMPOSITION, COATING COMPOSITION COMPRISING THE SAME AND MANUFACTURING METHOD THEREOF | August 2022 | June 2025 | Allow | 34 | 4 | 0 | Yes | No |
| 17821943 | PROPOFOL COMPOSITIONS AND METHODS OF USE | August 2022 | May 2024 | Abandon | 21 | 1 | 1 | No | No |
| 17888600 | SPIROHEPTANYL HYDANTOINS AS ROCK INHIBITORS | August 2022 | March 2024 | Allow | 19 | 1 | 0 | No | No |
| 17794781 | SALT OF ARYLAMINOPURINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | July 2022 | September 2025 | Abandon | 37 | 0 | 1 | No | No |
| 17866488 | COMPOSITIONS FOR IMPROVED NRF2 ACTIVATION AND METHODS OF THEIR USE | July 2022 | October 2025 | Abandon | 40 | 1 | 1 | No | No |
| 17811790 | CD38 MODULATORS AND METHODS OF USE THEREOF | July 2022 | May 2025 | Abandon | 34 | 2 | 1 | No | No |
| 17811731 | BICYCLIC COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | July 2022 | January 2024 | Allow | 19 | 1 | 1 | Yes | No |
| 17858562 | METHOD OF PREPARING PH-SENSITIVE CONTROLLED-RELEASE EMULSION HYDROGEL | July 2022 | June 2025 | Abandon | 36 | 4 | 0 | Yes | No |
| 17787680 | SALT FORM AND CRYSTAL FORM OF MUTANT IDH1 INHIBITOR AND PREPARATION METHOD THEREFOR | June 2022 | May 2025 | Allow | 35 | 0 | 1 | No | No |
| 17807372 | REHYDRATABLE, MORPHOLOGICALLY DIVERSE NANOCARRIER POWDERS | June 2022 | February 2026 | Abandon | 44 | 4 | 1 | Yes | No |
| 17783743 | POLYMER MATRIXES FOR DIFFERENT COMPOSITIONS OF MITOCHONDRIALLY TARGETED ANTIOXIDANTS | June 2022 | December 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17824478 | TOPICAL OTIC, OPHTHALMIC, AND NASAL CORTICOSTEROID FORMULATIONS | May 2022 | February 2024 | Allow | 21 | 2 | 0 | No | No |
| 17774989 | USE OF COMPOUND IN PREVENTING OR TREATING GRAFT VERSUS HOST DISEASE | May 2022 | December 2025 | Abandon | 43 | 1 | 0 | No | No |
| 17707975 | MULTIFUNCTIONAL WOOD PRESERVATIVE COMPOSITION AND WOOD PRESERVATION TREATMENT METHOD USING THE SAME | March 2022 | February 2025 | Abandon | 34 | 3 | 0 | No | No |
| 17760991 | BENZOTRIAZOLE COMPOUND, LIGHT ABSORBER, AND RESIN COMPOSITION | March 2022 | August 2025 | Allow | 41 | 1 | 1 | No | No |
| 17692153 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF PROTEIN KINASES | March 2022 | December 2023 | Abandon | 21 | 2 | 1 | No | No |
| 17668239 | COMPOSITIONS AND METHODS FOR MONITORING, DIAGNOSIS, PROGNOSIS, DETECTION, AND TREATMENT OF CANCER | February 2022 | January 2025 | Allow | 35 | 3 | 1 | Yes | No |
| 17665190 | POLYOXAZOLINE-LIPID CONJUGATES AND LIPID NANOPARTICLES AND PHARMACEUTICAL COMPOSITIONS INCLUDING SAME | February 2022 | October 2024 | Allow | 33 | 2 | 1 | No | No |
| 17628619 | Macrocyclic Compounds as Sting Agonists and Methods and Uses Thereof | January 2022 | August 2025 | Allow | 42 | 0 | 1 | No | No |
| 17627602 | SEROTONERGIC AGENT AND 5-HT1A-RECEPTOR ANTAGONIST | January 2022 | October 2025 | Abandon | 45 | 1 | 0 | No | No |
| 17597148 | MITOCHONDRIAL FUNCTION ACTIVATOR | December 2021 | November 2025 | Abandon | 47 | 1 | 1 | No | No |
| 17473967 | WATER-SOLUBLE CURCUMIN LIQUID AND PREPARATION METHOD AND APPLICATION THEREOF | September 2021 | September 2024 | Allow | 36 | 1 | 0 | Yes | No |
| 17434102 | P300/CBP HAT INHIBITORS AND METHODS FOR THEIR USE | August 2021 | November 2025 | Abandon | 51 | 1 | 1 | No | No |
| 17429510 | Method for Obtaining Gamma-Oryzanol | August 2021 | March 2026 | Abandon | 55 | 2 | 1 | No | No |
| 17262149 | AMINO ACID MINERAL COMPLEX HAVING IMMUNOPOTENTIATING ACTIVITY AND COMPOSITION FOR FOODS, PHARMACEUTICALS, OR FEEDS COMPRISING SAME | August 2021 | December 2025 | Allow | 59 | 3 | 1 | Yes | No |
| 17426277 | USE OF P1P DERIVATIVES AS THERAPEUTIC AGENT FOR SEPSIS | July 2021 | May 2025 | Abandon | 46 | 1 | 0 | No | No |
| 17425505 | PRE-NATAL BETA-CRYPTOXANTHIN BENEFITS CHILDREN | July 2021 | December 2024 | Abandon | 41 | 1 | 0 | No | No |
| 17310038 | 3-SUBSTITUTED PHENYLAMIDINE COMPOUNDS, PREPARATION AND USE THEREOF | July 2021 | October 2025 | Allow | 51 | 2 | 1 | No | No |
| 17356197 | METHODS AND SYSTEMS FOR PROVIDING A PERSONALIZED TREATMENT REGIMEN USING CANNABINOID OR PSYCHEDELIC COMPOUNDS | June 2021 | September 2025 | Abandon | 50 | 2 | 1 | No | No |
| 17311403 | CRYSTALLINE FORMS OF 1-(1,2-DIMETHYLPROPYL)-N-ETHYL-5-METHYL-N-PYRIDAZIN-4-YL-PYRAZOLE-4-CARBOXAMIDE | June 2021 | June 2025 | Allow | 48 | 2 | 0 | No | No |
| 17299648 | PYRAZOLOPYRIMIDINE PDE9 INHIBITORS | June 2021 | June 2025 | Allow | 48 | 2 | 1 | No | No |
| 17330386 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING FERROPTOSIS AND TREATING EXCITOTOXIC DISORDERS | May 2021 | September 2025 | Abandon | 52 | 2 | 1 | No | No |
| 17292600 | ANTIBIOTIC COMPOUNDS, METHODS OF MANUFACTURING THE SAME, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND USES THEREOF | May 2021 | October 2025 | Allow | 53 | 3 | 1 | Yes | No |
| 17309179 | TARGETING PLECKSTRIN-2 FOR TREATING CANCER | May 2021 | February 2026 | Allow | 57 | 3 | 1 | No | No |
| 17242530 | PREVENTION OF AGE RELATED CLONAL HEMATOPOIESIS AND DISEASES ASSOCIATED THEREWITH | April 2021 | December 2024 | Abandon | 43 | 1 | 0 | No | No |
| 17288626 | INHIBITORS OF HISTONE DEACETYLASE USEFUL FOR THE TREATMENT OR PREVENTION OF HIV INFECTION | April 2021 | December 2025 | Allow | 55 | 4 | 1 | No | No |
| 17286591 | 3-(1H-PYRAZOL-4-YL)PYRIDINE ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR | April 2021 | January 2024 | Allow | 33 | 1 | 0 | No | No |
| 17221866 | HIGH-PERFORMING METAL-FREE PRIMARY EXPLOSIVE | April 2021 | November 2023 | Allow | 31 | 1 | 0 | No | No |
| 17221552 | METHODS FOR THE TREATMENT OF BLADDER CANCER | April 2021 | February 2025 | Abandon | 47 | 1 | 1 | No | No |
| 17282218 | BIOMARKERS FOR A THERAPY COMPRISING A SORAFENIB COMPOUND | April 2021 | July 2025 | Allow | 51 | 3 | 1 | Yes | No |
| 17219719 | DOUBLE-CROSSLINKED SELF-HEALING HYDROGEL | March 2021 | January 2026 | Abandon | 57 | 4 | 0 | No | No |
| 17281567 | SUBSTITUTED PYRAZOLE FUSED RING DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | March 2021 | December 2025 | Allow | 57 | 4 | 1 | Yes | No |
| 17280633 | HETEROCYCLIC COMPOUND | March 2021 | December 2023 | Allow | 33 | 0 | 0 | No | No |
| 17206498 | METHODS AND COMPOSITIONS FOR TREATMENT OF PERIPHERAL NEUROPATHIES | March 2021 | September 2024 | Abandon | 42 | 2 | 0 | Yes | No |
| 17205466 | FLUTICASONE FUROATE IN THE TREATMENT OF COPD | March 2021 | July 2025 | Abandon | 52 | 2 | 0 | No | No |
| 17277702 | BORONIC ACID POLYMERS AND METHODS OF USE | March 2021 | April 2025 | Abandon | 49 | 2 | 0 | No | No |
| 17277156 | CANCER COMBINATION THERAPY USING QUINOLINE CARBOXAMIDE DERIVATIVE | March 2021 | May 2024 | Abandon | 38 | 1 | 0 | No | No |
| 17270770 | USE OF CICLOPIROX FOR INHIBITING HBV CORE ASSEMBLY | February 2021 | March 2025 | Abandon | 49 | 3 | 0 | No | No |
| 17172434 | USE OF A CREAM THAT PROTECTS AGAINST THE EFFECTS OF AGGRESSIVE CHEMICAL AGENTS IN CONTACT WITH THE SKIN | February 2021 | November 2025 | Abandon | 57 | 5 | 0 | No | No |
| 17266929 | METHOD OF DIAGNOSING AND TREATING ALZHEIMER DISEASE USING PLASMA TAU LEVEL IN CONJUNCTION WITH BETA-AMYLOID LEVEL AS DIAGNOSTIC INDEX | February 2021 | February 2025 | Abandon | 49 | 2 | 0 | No | No |
| 17170690 | AMINOPYRIDINE DERIVATIVES AND THEIR USE AS SELECTIVE ALK-2 INHIBITORS | February 2021 | January 2024 | Allow | 36 | 3 | 0 | No | Yes |
| 17265290 | INSECTICIDAL COMBINATIONS | February 2021 | November 2024 | Allow | 45 | 2 | 1 | No | No |
| 17263973 | METHOD FOR DYNAMIC FILTRATION OF A CROSS-LINKED HYDROGEL | January 2021 | December 2025 | Abandon | 59 | 4 | 1 | No | Yes |
| 17262989 | DERIVATIVES OF PAPAVERINE THAT ARE EFFECTIVE HYPOXIC TUMOR RADIOSENSITIZERS | January 2021 | January 2026 | Allow | 60 | 3 | 1 | No | No |
| 17263016 | PYRIDONE A2R ANTAGONISTS | January 2021 | April 2024 | Allow | 38 | 2 | 0 | Yes | No |
| 17047529 | PHARMACEUTICAL COMBINATION PRODUCTS COMPRISING A HISTONE DEACETYLASE (HDAC) INHIBITOR AND A TLR7 AGONIST AND/OR TLR8 AGONIST FOR THE TREATMENT OF CANCER | October 2020 | December 2024 | Abandon | 50 | 3 | 0 | No | No |
| 17044322 | QUINOLINE OR QUINAZOLINE COMPOUND AND APPLICATION THEREOF | September 2020 | September 2024 | Abandon | 48 | 4 | 0 | No | No |
| 16891427 | HYDROCHLORIDE SALT FORM FOR EZH2 INHIBITION | June 2020 | November 2024 | Abandon | 54 | 4 | 1 | No | No |
| 16815855 | USE OF VITAMIN K IN COMBINATION WITH ANTICOAGULANTS | March 2020 | March 2026 | Abandon | 60 | 10 | 0 | Yes | No |
| 16256522 | PROCESSES TO PRODUCE BRIVARACETAM | January 2019 | October 2024 | Allow | 60 | 11 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner ELENISTE, PIERRE PAUL.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 50.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the top 25% across the USPTO, indicating that filing appeals is particularly effective here. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner ELENISTE, PIERRE PAUL works in Art Unit 1622 and has examined 40 patent applications in our dataset. With an allowance rate of 45.0%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 50 months.
Examiner ELENISTE, PIERRE PAUL's allowance rate of 45.0% places them in the 9% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by ELENISTE, PIERRE PAUL receive 2.70 office actions before reaching final disposition. This places the examiner in the 79% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by ELENISTE, PIERRE PAUL is 50 months. This places the examiner in the 5% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +42.3% benefit to allowance rate for applications examined by ELENISTE, PIERRE PAUL. This interview benefit is in the 89% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 14.8% of applications are subsequently allowed. This success rate is in the 11% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 15.8% of cases where such amendments are filed. This entry rate is in the 17% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.
When applicants request a pre-appeal conference (PAC) with this examiner, 100.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 69% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 86% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 40.0% are granted (fully or in part). This grant rate is in the 29% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.